Last reviewed · How we verify
NCT05161611
Effect of Oral Zinc Sulfate on Jaundice in Neonates Admitted to Neonatal Intensive Care Unit
NA trial testing Zinc sulfate in Serum Bilirubin in 60 participants. Completed in 28 August 2022.
28 August 2022
Quick facts
| Lead sponsor | Makassed General Hospital |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | other |
| Enrollment | 60 |
| Start date | 17 December 2021 |
| Primary completion | 28 August 2022 |
| Estimated completion | 28 August 2022 |
| Sites | 1 location across Lebanon |
Drugs / interventions tested
- Zinc sulfate (ZINC SULFATE) — full drug profile →
- Placebo
- Phototherapy
Conditions studied
- Serum Bilirubin — all drugs for Serum Bilirubin →
Sponsor
Makassed General Hospital
Who can join
Adults 1 Hour to 1 Month, any sex, with Serum Bilirubin. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A randomized double-blind clinical trial will be performed in the neonatal intensive care unit of Makassed General Hospital in Beirut, Lebanon from December 2021 till August 2022. Randomized opaque envelopes to allocate the treatment will be used. The study will include neonates aged between 26 and 42 gestational weeks, who require phototherapy in the neonatal intensive care unit. Patients will be randomized into two groups.Both groups will receive standard conventional phototherapy, but the intervention group will receive 10 mg per day oral zinc sulfate until discharge.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05161611
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Zinc sulfate
Trials testing the same drug.
- NCT07383363 — Comparison of Efficacy and Safety of Vita 6 Versus Zinc Along With Applied Behavioural Therapy · NA · completed
- NCT07102836 — COMPARISON OF ZINC AND PROBIOTICS ON NEONATES WITH INDIRECT HYPERBILIRUBINEMIA UNDERGOING PHOTOTHERAPY · Phase 2 · recruiting
- NCT06517862 — Efficacy & Safety of Oral Adjuvants to Phototherapy in Neonatal Hyperbilirubinemia · Phase 4 · recruiting
- NCT06482034 — Effect of N-acetyl Cysteine and Zinc in Management of Head and Neck Cancer Radiotherapy Induced Oral Mucositis · Phase 2 · completed
- NCT05395143 — Study to Assess the Effect of Zinc in Atorvastatin Treated Hyperlipidemic Patients · Phase 2 · unknown
Other Makassed General Hospital trials
Trials by the same sponsor.
- NCT07201883 — Chewing Gum vs. Ondansetron as Rescue Treatment for PONV in Female Patients · Phase 1 · active not recruiting
- NCT07182110 — Dexamethasone-Enhanced TAP Block in Lapchole · Phase 1 · active not recruiting
- NCT07049835 — Ilioinguinal Nerve Block With Local Anesthetic vs. Placebo in Inguinal Hernia Repair Under Spinal Anesthesia · Phase 1 · active not recruiting
- NCT06963229 — Spinal Anesthesia Vs. Neve Block in Risk of Cognitive Decline · NA · active not recruiting
- NCT06917898 — Fentanyl Versus Midazolam as an Adjunct to Spinal Anesthesia · Phase 1 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05161611 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Makassed General Hospital
- Last refreshed: 30 August 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05161611.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing